| Chronic Lymphocytic Leukemia |
0 |
0.8 |
| Food and Drug Administration (FDA) |
0 |
1 |
| Non-Hodgkin Lymphoma (NHL) |
0 |
0.66 |
| Lymphoma |
0 |
1 |
| Follicular Lymphoma |
0 |
1 |
| Biologic Therapy |
0 |
0.27 |
| Clinical Research |
0 |
0.21 |
| Leukemia |
0 |
0.21 |
| Monoclonal Antibody |
0 |
0.8 |
| Cancer |
0 |
0.16 |
| Patient Safety |
0 |
0.9 |
| Refractory |
0 |
0.11 |
| Diarrhea |
0 |
0.09 |
| Adverse Effects |
0 |
0.05 |
| Colitis |
0 |
0.05 |
| Drug and Treatment Safety |
0 |
0.05 |
| Grant |
0 |
0.05 |
| Inflammatory Bowel Disease |
0 |
0.05 |
| Pneumonia |
0 |
0.05 |
| Sepsis |
0 |
0.05 |
| Urinary Tract Infection |
0 |
0.05 |